Helius Medical Technologies, Inc. will participate in


NEWTOWN, Pa., July 7, 2021 (GLOBE NEWSWIRE) – Helius Medical Technologies, Inc. (Nasdaq: HSDT) (TSX: HSM) (“Helius” or the “Company”), a wellness-focused neurotech company neurology, today announced its participation in the Society for Brain Mapping and Therapeutics Annual World Congress, July 8-11e in Los Angeles, California.

The Company has been selected to receive the Technology Pioneer Award at the event, an award presented by the Company to pioneering companies that have facilitated the development of pioneering technologies through interdisciplinary approaches that have had an unprecedented impact on diagnosis, treatment and delivery of health care.

Dr. Jonathan Sackier, Co-Founder and Medical Advisor of Hélius, will host a presentation at the event entitled: From porpoise to PoNS ™: the Varolio bridge and translingual neuromodulation to treat symptoms of balance and walking. The presentation will include a discussion of the history of neuromodulation, the science behind Helius’ PoNS technology, data from trials in experimental and clinical settings – including trials focusing on multiple sclerosis, traumatic brain injury , stroke and cerebral palsy – and recent regulatory approvals. The presentation will take place on July 11e at 10 a.m. Pacific time.

About Helius Medical Technologies, Inc.

Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s goal is to develop, license and acquire unique, non-invasive platform technologies that amplify the brain’s ability to heal itself. The company’s first commercial product is the Portable Neuromodulation Stimulator (PoNSMT). For more information, visit www.heliusmedical.com.

About the PoNS ™ device and PoNS ™ processing

The portable neuromodulation stimulator (PoNSMT) is an innovative non-surgical device, comprising a controller and a mouthpiece, that delivers electrical stimulation to the surface of the tongue to treat walking deficit. The PoNS device is indicated in the United States for the short-term treatment of impaired walking due to mild to moderate symptoms of multiple sclerosis (“MS”) and should be used in addition to a therapeutic exercise program. supervised in patients 22 years and older by prescription only. It is authorized for sale in Canada as a Class II, non-implantable medical device for the short-term treatment (14 weeks) of gait deficiency due to mild and moderate symptoms of MS and chronic gait deficiency. balance due to mild to moderate traumatic brain injury (“mmTBI”) disorder and should be used in conjunction with physical therapy. PoNS is an investigational medical device in the European Union (“EU”) and Australia (“AUS”). It is currently under pre-market review by the AUS Therapeutic Goods Administration.


Certain statements contained in this press release are not based on historical fact and constitute forward-looking statements or forward-looking information within the meaning of the United States Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements other than statements of historical fact included in this press release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by words such as “believe”, “continue”, “”, phrases. These forward-looking statements include, among others, statements regarding the future strategic and operational execution of the Company, the next phase of the Company’s market development activities, the clinical and regulatory development plans for the PoNS device, and the timeline. and the success of the Company’s marketing efforts. in the USA.

These statements involve known and unknown risks and uncertainties. There can be no assurance that such statements will prove to be accurate and that actual results and future events could differ materially from those expressed or implied by such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include uncertainties regarding the Company’s capital requirements to meet its business objectives, the impact of the COVID-19 pandemic, the ability to the Company to train physiotherapists in overseeing the use of the PoNS treatment, the Company’s ability to contract with rehabilitation clinics, the Company’s ability to obtain national Medicare coverage and obtain a code of reimbursement so that the PoNS device is covered by Medicare and Medicaid, the Company’s ability to build an internal business infrastructure, knowledge of the PoNS device, future clinical trials and clinical development process, manufacturing risks and the supply chain procurement, potential changes to the MCIT program, product development process, and the review and approval process of FDA regulatory submissions, other development activities, ongoing government regulations and other risks detailed from time to time in the “Risk Factors” sections of the report Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, its Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 and its other filings with the United States Securities and Exchange Commission. United States and Canadian securities regulatory authorities, which can be obtained at www.sec.gov or www.sedar.com. The reader is cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements contained in this press release are made as of the date of this press release and the Company assumes no obligation to update any forward-looking statements or to update the reasons why actual results could differ from these. statements, except to the extent required by law.

The Toronto Stock Exchange has not reviewed and accepts no responsibility for the adequacy or accuracy of the contents of this press release.


Source link


Leave A Reply